Hayman’s group developed a prodrug by coupling an acetylated lysine group to puromycin which can be activated by the endogenous protease cathepsin L. In vivo anti-tumor experiments indicated that the designed prodrug exhibited efficient tumor growth inhibition in cancer models with high cathepsin L activity (Ueki et al., 2013). This evidence concerns the gene CTSL and neoplasm.